Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis
Human immunodeficiency virus (HIV) infection is the strongest risk factor for developing tuberculosis and has fuelled its resurgence, especially in sub-Saharan Africa. In 2010, there were an estimated 1.1 million incident cases of tuberculosis among the 34 million people living with HIV worldwide. A...
Gespeichert in:
| Veröffentlicht in: | PLoS medicine 2012-07, Vol.9 (7), p.e1001270 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | e1001270 |
| container_title | PLoS medicine |
| container_volume | 9 |
| creator | Suthar, Amitabh B Lawn, Stephen D del Amo, Julia Getahun, Haileyesus Dye, Christopher Sculier, Delphine Sterling, Timothy R Chaisson, Richard E Williams, Brian G Harries, Anthony D Granich, Reuben M |
| description | Human immunodeficiency virus (HIV) infection is the strongest risk factor for developing tuberculosis and has fuelled its resurgence, especially in sub-Saharan Africa. In 2010, there were an estimated 1.1 million incident cases of tuberculosis among the 34 million people living with HIV worldwide. Antiretroviral therapy has substantial potential to prevent HIV-associated tuberculosis. We conducted a systematic review of studies that analysed the impact of antiretroviral therapy on the incidence of tuberculosis in adults with HIV infection.
PubMed, Embase, African Index Medicus, LILACS, and clinical trial registries were systematically searched. Randomised controlled trials, prospective cohort studies, and retrospective cohort studies were included if they compared tuberculosis incidence by antiretroviral therapy status in HIV-infected adults for a median of over 6 mo in developing countries. For the meta-analyses there were four categories based on CD4 counts at antiretroviral therapy initiation: (1) less than 200 cells/µl, (2) 200 to 350 cells/µl, (3) greater than 350 cells/µl, and (4) any CD4 count. Eleven studies met the inclusion criteria. Antiretroviral therapy is strongly associated with a reduction in the incidence of tuberculosis in all baseline CD4 count categories: (1) less than 200 cells/µl (hazard ratio [HR] 0.16, 95% confidence interval [CI] 0.07 to 0.36), (2) 200 to 350 cells/µl (HR 0.34, 95% CI 0.19 to 0.60), (3) greater than 350 cells/µl (HR 0.43, 95% CI 0.30 to 0.63), and (4) any CD4 count (HR 0.35, 95% CI 0.28 to 0.44). There was no evidence of hazard ratio modification with respect to baseline CD4 count category (p = 0.20).
Antiretroviral therapy is strongly associated with a reduction in the incidence of tuberculosis across all CD4 count strata. Earlier initiation of antiretroviral therapy may be a key component of global and national strategies to control the HIV-associated tuberculosis syndemic.
International Prospective Register of Systematic Reviews CRD42011001209 Please see later in the article for the Editors' Summary. |
| doi_str_mv | 10.1371/journal.pmed.1001270 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1288096011</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A299885123</galeid><doaj_id>oai_doaj_org_article_8356d855b950445483a790f1fbc2f4f6</doaj_id><sourcerecordid>A299885123</sourcerecordid><originalsourceid>FETCH-LOGICAL-c720t-a86e097e2b86a3733096fd54797132f355ecd460b668faa118b79d25bf82e4e23</originalsourceid><addsrcrecordid>eNqVk11v0zAUhiMEYmPwDxBYQkJw0eKPOLG5QKomYJUmJvGxW-sksVtXaZzZTkf_PS7NphZxAVe27Oe8Puc9Pln2nOApYSV5t3KD76Cd9mvdTAnGhJb4QXZKeC4npCiLhwf7k-xJCCuMqcQSP85OKJWEYEJOMzfrovU6erexHloUl9pDv0XGedR7vdHp2nXIGRSHSvt6aF2wAdkOQTO0MaBbG5foYn79HgEK2xD1GqKtUQq1-hZB16C1jjCBlOo2RT7NHhlog342rmfZj08fv59fTC6vPs_PZ5eTuqQ4TkAUGstS00oUwErGsCxMw_NSloRRwzjXdZMXuCoKYQAIEVUpG8orI6jONWVn2cu9bp8SVqNXQREqRJJKpSdivicaByvVe7sGv1UOrPp94PxCgU-ltFoJxotGcF5JjvOc54JBKbEhpqqpyU2RtD6Mrw1VakedXEtmHoke33R2qRZuo1iO89SJJPBmFPDuZtAhqrUNtW5b6LQbUt6M8IIQynZ5v_oD_Xt1I7WAVIDtjEvv1jtRNaNSCsGTWKLeHlG166L-GRcwhKDm377-B_vl39mr62P29QG71NDGZXDtsPt34RjM92DtXQhem3t_CVa7kbgzQu1GQo0jkcJeHPbmPuhuBtgvPEIFuA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1288096011</pqid></control><display><type>article</type><title>Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Public Library of Science (PLoS)</source><creator>Suthar, Amitabh B ; Lawn, Stephen D ; del Amo, Julia ; Getahun, Haileyesus ; Dye, Christopher ; Sculier, Delphine ; Sterling, Timothy R ; Chaisson, Richard E ; Williams, Brian G ; Harries, Anthony D ; Granich, Reuben M</creator><creatorcontrib>Suthar, Amitabh B ; Lawn, Stephen D ; del Amo, Julia ; Getahun, Haileyesus ; Dye, Christopher ; Sculier, Delphine ; Sterling, Timothy R ; Chaisson, Richard E ; Williams, Brian G ; Harries, Anthony D ; Granich, Reuben M</creatorcontrib><description>Human immunodeficiency virus (HIV) infection is the strongest risk factor for developing tuberculosis and has fuelled its resurgence, especially in sub-Saharan Africa. In 2010, there were an estimated 1.1 million incident cases of tuberculosis among the 34 million people living with HIV worldwide. Antiretroviral therapy has substantial potential to prevent HIV-associated tuberculosis. We conducted a systematic review of studies that analysed the impact of antiretroviral therapy on the incidence of tuberculosis in adults with HIV infection.
PubMed, Embase, African Index Medicus, LILACS, and clinical trial registries were systematically searched. Randomised controlled trials, prospective cohort studies, and retrospective cohort studies were included if they compared tuberculosis incidence by antiretroviral therapy status in HIV-infected adults for a median of over 6 mo in developing countries. For the meta-analyses there were four categories based on CD4 counts at antiretroviral therapy initiation: (1) less than 200 cells/µl, (2) 200 to 350 cells/µl, (3) greater than 350 cells/µl, and (4) any CD4 count. Eleven studies met the inclusion criteria. Antiretroviral therapy is strongly associated with a reduction in the incidence of tuberculosis in all baseline CD4 count categories: (1) less than 200 cells/µl (hazard ratio [HR] 0.16, 95% confidence interval [CI] 0.07 to 0.36), (2) 200 to 350 cells/µl (HR 0.34, 95% CI 0.19 to 0.60), (3) greater than 350 cells/µl (HR 0.43, 95% CI 0.30 to 0.63), and (4) any CD4 count (HR 0.35, 95% CI 0.28 to 0.44). There was no evidence of hazard ratio modification with respect to baseline CD4 count category (p = 0.20).
Antiretroviral therapy is strongly associated with a reduction in the incidence of tuberculosis across all CD4 count strata. Earlier initiation of antiretroviral therapy may be a key component of global and national strategies to control the HIV-associated tuberculosis syndemic.
International Prospective Register of Systematic Reviews CRD42011001209 Please see later in the article for the Editors' Summary.</description><identifier>ISSN: 1549-1676</identifier><identifier>ISSN: 1549-1277</identifier><identifier>EISSN: 1549-1676</identifier><identifier>DOI: 10.1371/journal.pmed.1001270</identifier><identifier>PMID: 22911011</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adult ; Analysis ; Anti-HIV Agents - therapeutic use ; Antiretroviral drugs ; antiretroviral therapy ; Antiretroviral Therapy, Highly Active ; Care and treatment ; CD4 Lymphocyte Count ; Development and progression ; Drug therapy ; Highly active antiretroviral therapy ; HIV ; HIV infection ; HIV Infections - complications ; HIV Infections - drug therapy ; HIV Infections - immunology ; Human immunodeficiency virus ; Humans ; Infection ; Medicine ; Mycobacterium ; Quality Assurance, Health Care - standards ; Randomized Controlled Trials as Topic ; Reviews ; Studies ; Tuberculosis ; Tuberculosis - complications ; Tuberculosis - drug therapy ; Tuberculosis - prevention & control</subject><ispartof>PLoS medicine, 2012-07, Vol.9 (7), p.e1001270</ispartof><rights>COPYRIGHT 2012 Public Library of Science</rights><rights>Suthar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, et al. (2012) Antiretroviral Therapy for Prevention of Tuberculosis in Adults with HIV: A Systematic Review and Meta-Analysis. PLoS Med 9(7): e1001270. doi:10.1371/journal.pmed.1001270</rights><rights>2012 Suthar et al 2012 Suthar et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c720t-a86e097e2b86a3733096fd54797132f355ecd460b668faa118b79d25bf82e4e23</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404110/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404110/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79569,79570</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22911011$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Suthar, Amitabh B</creatorcontrib><creatorcontrib>Lawn, Stephen D</creatorcontrib><creatorcontrib>del Amo, Julia</creatorcontrib><creatorcontrib>Getahun, Haileyesus</creatorcontrib><creatorcontrib>Dye, Christopher</creatorcontrib><creatorcontrib>Sculier, Delphine</creatorcontrib><creatorcontrib>Sterling, Timothy R</creatorcontrib><creatorcontrib>Chaisson, Richard E</creatorcontrib><creatorcontrib>Williams, Brian G</creatorcontrib><creatorcontrib>Harries, Anthony D</creatorcontrib><creatorcontrib>Granich, Reuben M</creatorcontrib><title>Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis</title><title>PLoS medicine</title><addtitle>PLoS Med</addtitle><description>Human immunodeficiency virus (HIV) infection is the strongest risk factor for developing tuberculosis and has fuelled its resurgence, especially in sub-Saharan Africa. In 2010, there were an estimated 1.1 million incident cases of tuberculosis among the 34 million people living with HIV worldwide. Antiretroviral therapy has substantial potential to prevent HIV-associated tuberculosis. We conducted a systematic review of studies that analysed the impact of antiretroviral therapy on the incidence of tuberculosis in adults with HIV infection.
PubMed, Embase, African Index Medicus, LILACS, and clinical trial registries were systematically searched. Randomised controlled trials, prospective cohort studies, and retrospective cohort studies were included if they compared tuberculosis incidence by antiretroviral therapy status in HIV-infected adults for a median of over 6 mo in developing countries. For the meta-analyses there were four categories based on CD4 counts at antiretroviral therapy initiation: (1) less than 200 cells/µl, (2) 200 to 350 cells/µl, (3) greater than 350 cells/µl, and (4) any CD4 count. Eleven studies met the inclusion criteria. Antiretroviral therapy is strongly associated with a reduction in the incidence of tuberculosis in all baseline CD4 count categories: (1) less than 200 cells/µl (hazard ratio [HR] 0.16, 95% confidence interval [CI] 0.07 to 0.36), (2) 200 to 350 cells/µl (HR 0.34, 95% CI 0.19 to 0.60), (3) greater than 350 cells/µl (HR 0.43, 95% CI 0.30 to 0.63), and (4) any CD4 count (HR 0.35, 95% CI 0.28 to 0.44). There was no evidence of hazard ratio modification with respect to baseline CD4 count category (p = 0.20).
Antiretroviral therapy is strongly associated with a reduction in the incidence of tuberculosis across all CD4 count strata. Earlier initiation of antiretroviral therapy may be a key component of global and national strategies to control the HIV-associated tuberculosis syndemic.
International Prospective Register of Systematic Reviews CRD42011001209 Please see later in the article for the Editors' Summary.</description><subject>Adult</subject><subject>Analysis</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretroviral drugs</subject><subject>antiretroviral therapy</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Care and treatment</subject><subject>CD4 Lymphocyte Count</subject><subject>Development and progression</subject><subject>Drug therapy</subject><subject>Highly active antiretroviral therapy</subject><subject>HIV</subject><subject>HIV infection</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - immunology</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infection</subject><subject>Medicine</subject><subject>Mycobacterium</subject><subject>Quality Assurance, Health Care - standards</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Reviews</subject><subject>Studies</subject><subject>Tuberculosis</subject><subject>Tuberculosis - complications</subject><subject>Tuberculosis - drug therapy</subject><subject>Tuberculosis - prevention & control</subject><issn>1549-1676</issn><issn>1549-1277</issn><issn>1549-1676</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqVk11v0zAUhiMEYmPwDxBYQkJw0eKPOLG5QKomYJUmJvGxW-sksVtXaZzZTkf_PS7NphZxAVe27Oe8Puc9Pln2nOApYSV5t3KD76Cd9mvdTAnGhJb4QXZKeC4npCiLhwf7k-xJCCuMqcQSP85OKJWEYEJOMzfrovU6erexHloUl9pDv0XGedR7vdHp2nXIGRSHSvt6aF2wAdkOQTO0MaBbG5foYn79HgEK2xD1GqKtUQq1-hZB16C1jjCBlOo2RT7NHhlog342rmfZj08fv59fTC6vPs_PZ5eTuqQ4TkAUGstS00oUwErGsCxMw_NSloRRwzjXdZMXuCoKYQAIEVUpG8orI6jONWVn2cu9bp8SVqNXQREqRJJKpSdivicaByvVe7sGv1UOrPp94PxCgU-ltFoJxotGcF5JjvOc54JBKbEhpqqpyU2RtD6Mrw1VakedXEtmHoke33R2qRZuo1iO89SJJPBmFPDuZtAhqrUNtW5b6LQbUt6M8IIQynZ5v_oD_Xt1I7WAVIDtjEvv1jtRNaNSCsGTWKLeHlG166L-GRcwhKDm377-B_vl39mr62P29QG71NDGZXDtsPt34RjM92DtXQhem3t_CVa7kbgzQu1GQo0jkcJeHPbmPuhuBtgvPEIFuA</recordid><startdate>20120701</startdate><enddate>20120701</enddate><creator>Suthar, Amitabh B</creator><creator>Lawn, Stephen D</creator><creator>del Amo, Julia</creator><creator>Getahun, Haileyesus</creator><creator>Dye, Christopher</creator><creator>Sculier, Delphine</creator><creator>Sterling, Timothy R</creator><creator>Chaisson, Richard E</creator><creator>Williams, Brian G</creator><creator>Harries, Anthony D</creator><creator>Granich, Reuben M</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISN</scope><scope>ISR</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7QL</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>5PM</scope><scope>DOA</scope><scope>CZK</scope></search><sort><creationdate>20120701</creationdate><title>Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis</title><author>Suthar, Amitabh B ; Lawn, Stephen D ; del Amo, Julia ; Getahun, Haileyesus ; Dye, Christopher ; Sculier, Delphine ; Sterling, Timothy R ; Chaisson, Richard E ; Williams, Brian G ; Harries, Anthony D ; Granich, Reuben M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c720t-a86e097e2b86a3733096fd54797132f355ecd460b668faa118b79d25bf82e4e23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Analysis</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretroviral drugs</topic><topic>antiretroviral therapy</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Care and treatment</topic><topic>CD4 Lymphocyte Count</topic><topic>Development and progression</topic><topic>Drug therapy</topic><topic>Highly active antiretroviral therapy</topic><topic>HIV</topic><topic>HIV infection</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - immunology</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infection</topic><topic>Medicine</topic><topic>Mycobacterium</topic><topic>Quality Assurance, Health Care - standards</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Reviews</topic><topic>Studies</topic><topic>Tuberculosis</topic><topic>Tuberculosis - complications</topic><topic>Tuberculosis - drug therapy</topic><topic>Tuberculosis - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Suthar, Amitabh B</creatorcontrib><creatorcontrib>Lawn, Stephen D</creatorcontrib><creatorcontrib>del Amo, Julia</creatorcontrib><creatorcontrib>Getahun, Haileyesus</creatorcontrib><creatorcontrib>Dye, Christopher</creatorcontrib><creatorcontrib>Sculier, Delphine</creatorcontrib><creatorcontrib>Sterling, Timothy R</creatorcontrib><creatorcontrib>Chaisson, Richard E</creatorcontrib><creatorcontrib>Williams, Brian G</creatorcontrib><creatorcontrib>Harries, Anthony D</creatorcontrib><creatorcontrib>Granich, Reuben M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Canada</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><collection>PLoS Medicine</collection><jtitle>PLoS medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Suthar, Amitabh B</au><au>Lawn, Stephen D</au><au>del Amo, Julia</au><au>Getahun, Haileyesus</au><au>Dye, Christopher</au><au>Sculier, Delphine</au><au>Sterling, Timothy R</au><au>Chaisson, Richard E</au><au>Williams, Brian G</au><au>Harries, Anthony D</au><au>Granich, Reuben M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis</atitle><jtitle>PLoS medicine</jtitle><addtitle>PLoS Med</addtitle><date>2012-07-01</date><risdate>2012</risdate><volume>9</volume><issue>7</issue><spage>e1001270</spage><pages>e1001270-</pages><issn>1549-1676</issn><issn>1549-1277</issn><eissn>1549-1676</eissn><abstract>Human immunodeficiency virus (HIV) infection is the strongest risk factor for developing tuberculosis and has fuelled its resurgence, especially in sub-Saharan Africa. In 2010, there were an estimated 1.1 million incident cases of tuberculosis among the 34 million people living with HIV worldwide. Antiretroviral therapy has substantial potential to prevent HIV-associated tuberculosis. We conducted a systematic review of studies that analysed the impact of antiretroviral therapy on the incidence of tuberculosis in adults with HIV infection.
PubMed, Embase, African Index Medicus, LILACS, and clinical trial registries were systematically searched. Randomised controlled trials, prospective cohort studies, and retrospective cohort studies were included if they compared tuberculosis incidence by antiretroviral therapy status in HIV-infected adults for a median of over 6 mo in developing countries. For the meta-analyses there were four categories based on CD4 counts at antiretroviral therapy initiation: (1) less than 200 cells/µl, (2) 200 to 350 cells/µl, (3) greater than 350 cells/µl, and (4) any CD4 count. Eleven studies met the inclusion criteria. Antiretroviral therapy is strongly associated with a reduction in the incidence of tuberculosis in all baseline CD4 count categories: (1) less than 200 cells/µl (hazard ratio [HR] 0.16, 95% confidence interval [CI] 0.07 to 0.36), (2) 200 to 350 cells/µl (HR 0.34, 95% CI 0.19 to 0.60), (3) greater than 350 cells/µl (HR 0.43, 95% CI 0.30 to 0.63), and (4) any CD4 count (HR 0.35, 95% CI 0.28 to 0.44). There was no evidence of hazard ratio modification with respect to baseline CD4 count category (p = 0.20).
Antiretroviral therapy is strongly associated with a reduction in the incidence of tuberculosis across all CD4 count strata. Earlier initiation of antiretroviral therapy may be a key component of global and national strategies to control the HIV-associated tuberculosis syndemic.
International Prospective Register of Systematic Reviews CRD42011001209 Please see later in the article for the Editors' Summary.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>22911011</pmid><doi>10.1371/journal.pmed.1001270</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1549-1676 |
| ispartof | PLoS medicine, 2012-07, Vol.9 (7), p.e1001270 |
| issn | 1549-1676 1549-1277 1549-1676 |
| language | eng |
| recordid | cdi_plos_journals_1288096011 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Public Library of Science (PLoS) |
| subjects | Adult Analysis Anti-HIV Agents - therapeutic use Antiretroviral drugs antiretroviral therapy Antiretroviral Therapy, Highly Active Care and treatment CD4 Lymphocyte Count Development and progression Drug therapy Highly active antiretroviral therapy HIV HIV infection HIV Infections - complications HIV Infections - drug therapy HIV Infections - immunology Human immunodeficiency virus Humans Infection Medicine Mycobacterium Quality Assurance, Health Care - standards Randomized Controlled Trials as Topic Reviews Studies Tuberculosis Tuberculosis - complications Tuberculosis - drug therapy Tuberculosis - prevention & control |
| title | Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T09%3A25%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiretroviral%20therapy%20for%20prevention%20of%20tuberculosis%20in%20adults%20with%20HIV:%20a%20systematic%20review%20and%20meta-analysis&rft.jtitle=PLoS%20medicine&rft.au=Suthar,%20Amitabh%20B&rft.date=2012-07-01&rft.volume=9&rft.issue=7&rft.spage=e1001270&rft.pages=e1001270-&rft.issn=1549-1676&rft.eissn=1549-1676&rft_id=info:doi/10.1371/journal.pmed.1001270&rft_dat=%3Cgale_plos_%3EA299885123%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1288096011&rft_id=info:pmid/22911011&rft_galeid=A299885123&rft_doaj_id=oai_doaj_org_article_8356d855b950445483a790f1fbc2f4f6&rfr_iscdi=true |